Safran SA (0IU8)
London Stock Exchange · UK · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 273.85 |
|---|---|
| 52-week range | 261.60 – 368.90 |
| Return, 1 month / 3 months | −18.5% / −18.3% |
| Return, 1 year / 3 years | −8.9% / +92.6% |
| Trend | Below its 200-day average |
| RSI (14) | 22 |
| Volatility (1 year) | 34.4% |
| Worst drawdown (1 year) | -25.4% |
| Average daily value traded | 64.65M EUR |
| Dividend yield | 1.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Safran is a French aerospace and defence company. It designs and builds aircraft engines, including commercial jet engines made through its partnership with General Electric, and supplies engines for helicopters and military aircraft. It also makes landing gear, wheels and brakes, cabin equipment and avionics, and provides defence electronics and security systems. Its customers are aircraft manufacturers, airlines, helicopter operators and armed forces around the world, and the company is based in France.
The shares are listed on the London Stock Exchange in UK under the code 0IU8, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Safran SA (0IU8) trades on the London Stock Exchange in UK. It last closed at EUR 273.85 on 27 October 2026.
Its price-based Market X-Ray is 50 out of 100 (a fair price profile), ranking 2,036 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 8.9% and over the last three months it fell 18.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 40 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -13.2% | ||
| From 52-week high | -24.6% | ||
| Momentum | 42 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -18.3% | ||
| 6-month return | 1.8% | ||
| 12-month return, skipping the last month | 11.8% | ||
| Stability (higher is calmer) | 55 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 34.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.4% | ||
| Liquidity | 86 · Strong | Trades actively. | |
| Average daily value traded | 64.65M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 31 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.2% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | −12.6% |
|---|---|
| 1 month | −18.5% |
| 3 months | −18.3% |
| 6 months | +1.8% |
| 1 year | −8.9% |
| 3 years | +92.6% |
| 5 years | +156.4% |
Signals
| 50-day / 200-day average | 325.58 / 315.66 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 8.18 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 26 May 2026 | EUR 3.3500 |
| 27 May 2025 | EUR 2.9000 |
| 28 May 2024 | EUR 2.2000 |
| 30 May 2023 | EUR 1.3500 |
| 31 May 2022 | EUR 0.5000 |
| 31 May 2021 | EUR 0.4300 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.